欧洲婴儿型草酸盐沉着症结局随时间的改善:来自OxalEurope登记处的数据
该回顾性登记研究分析1980至2018年出生的95例婴儿型草酸盐沉着症患者,中位起病年龄0.4岁,5年生存率69%,2000年后出生者生存率显著更高,96%筛查患者出现全身性草酸盐沉着症,家族内表型变异需进一步研究。
要点
- 婴儿型草酸盐沉着症起病早,中位起病年龄0.4岁,5年生存率69%。
- 2000年后出生患者生存率显著高于2000年前出生者。
- 96%筛查患者出现全身性草酸盐沉着症,家族内表型变异需进一步研究。
核心结论
- 几乎所有筛查的婴儿型草酸盐沉着症患者均出现全身性疾病,死亡率仍高但随时间显著改善,新疗法可能进一步改善。
- 家族内表型变异需进一步研究。
研究设计与样本
- 回顾性登记研究,使用OxalEurope登记处数据,纳入1980至2018年出生的95例1岁前起病的PH1相关ESKD患者。
主要发现
- 中位(IQR)起病年龄为0.4(0.3-0.5)岁。
- 89例中27例(30%)死亡,中位死亡年龄1.4(0.6-2.0)岁,5年患者生存率69%。
- 56例筛查患者中54例(96%)出现全身性草酸盐沉着症。
- 首次移植中位年龄1.7(1.3-2.9)岁,42例为联合肝肾移植,23例肝移植为序贯方案的一部分,两种策略生存率相似。
- 2000年后出生患者生存率显著更高;14个家庭存在家族内表型变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Infantile oxalosis is the most severe form of primary hyperoxaluria type 1 (PH1), with onset of end-stage kidney disease (ESKD) during infancy. We aimed to analyze the outcome of these patients as our current understanding is limited owing to a paucity of reports. METHODS: A retrospective registry study was conducted using data from the OxalEurope registry. All PH1 patients with ESKD onset at age <1 year were analyzed. RESULTS: We identified 95 patients born between 1980 and 2018 with infantile oxalosis. Median (interquartile range [IQR]) age at ESKD was 0.4 (0.3-0.5) year. There were 4 patients diagnosed by family screening who developed ESKD despite early diagnosis. There were 11 patients who had biallelic missense mutations associated with vitamin B6 responsiveness. Of 89 patients, 27 (30%) died at a median age of 1.4 (0.6-2.0) years (5-year patient survival of 69%). Systemic oxalosis was described in 54 of 56 screened patients (96%). First transplantation was performed at a median age of 1.7 (1.3-2.9) years. In 42 cases, this procedure was a combined liver-kidney transplantation (LKTx), and in 23 cases, liver transplantations (LTx) was part of a sequential procedure. Survival rates of both strategies were similar. Patient survival was significantly higher in patients born after 2000. Intrafamilial phenotypic variability was present in 14 families of patients with infantile oxalosis. CONCLUSION: Nearly all screened patients with infantile oxalosis developed systemic disease. Mortality is still high but has significantly improved over time and might further improve under new therapies. The intrafamilial phenotypic variability warrants further investigation.
引用
- Deesker LJ, Garrelfs SF, Mandrile G, et al. Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. Kidney Int Rep. 2022. PMID: 35812297. doi:10.1016/j.ekir.2022.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。